Octreotide costs up to $10,000/month. This provider's guide covers manufacturer programs, copay cards, generics, and strategies to help patients afford treatment.
For patients on Octreotide, cost is more than an inconvenience — it's a barrier to adherence. When a medication costs anywhere from $3,000 to $10,000 per month depending on the formulation, even patients with insurance can face significant out-of-pocket burden. Patients without adequate coverage may skip doses, delay refills, or abandon treatment altogether.
As a prescriber, you're uniquely positioned to intervene before cost becomes a clinical problem. This guide covers the savings programs, generic options, and workflow strategies that can make Octreotide more accessible for your patients.
Understanding the cost landscape helps you anticipate where patients will hit barriers:
For commercially insured patients, copays on specialty tiers can range from $100 to $500+ per month even with coverage. Medicare Part B patients may face 20% coinsurance on physician-administered LAR injections. Uninsured patients face the full cash price.
The gap between "covered" and "affordable" is where most patients struggle — and where your guidance matters most.
Novartis offers a copay assistance card for commercially insured patients on Sandostatin LAR Depot, providing up to $15,000 per calendar year in copay assistance. This can eliminate or significantly reduce monthly copays for many patients.
Key details:
For uninsured or underinsured patients who meet income criteria, the Novartis Patient Assistance Foundation provides Sandostatin at no cost. This is one of the most robust manufacturer PAPs in the specialty space.
Eligibility:
Your office will need to complete a brief enrollment form and provide a prescription. Turnaround is typically 1–2 weeks for initial approval.
Amryt Pharma offers patient support programs for Mycapssa, including copay assistance and access support. Given the $8,000–$10,000 monthly cost, this support is essential for any patient transitioning to oral Octreotide.
Several independent foundations provide copay assistance for patients with neuroendocrine tumors, acromegaly, and related conditions:
These foundations typically help with copays and coinsurance for insured patients. Eligibility is usually based on income, diagnosis, and insurance status.
For patients paying cash for generic immediate-release Octreotide injection, discount cards can reduce costs further:
Important caveat: These cards are most useful for the relatively affordable generic immediate-release injection. They do not meaningfully reduce the cost of LAR formulations or Mycapssa, which are typically $3,000+ per month and dispensed through specialty pharmacies.
For a comprehensive patient-facing guide, refer patients to our post on how to save money on Octreotide.
The generic landscape has improved significantly:
When insurance requires step therapy, starting with generic immediate-release Octreotide satisfies this requirement while keeping costs low during the stabilization period.
If Octreotide is cost-prohibitive or unavailable, consider these therapeutic alternatives based on indication:
For a detailed comparison, see our post on alternatives to Octreotide.
The most effective cost intervention is the one that happens before the patient leaves your office with a prescription they can't afford. Here are practical workflow strategies:
A simple question works: "Are you having any difficulty affording your Octreotide?" Patients often won't volunteer this information — they'll just skip doses quietly. Asking directly gives permission to discuss it.
Your specialty pharmacy representatives can check benefits, estimate copays, and initiate prior authorizations before the patient fills. Building a relationship with 1–2 specialty pharmacies that handle Octreotide well saves everyone time.
Don't let PA denials create treatment gaps. Submit prior authorization before switching formulations and keep documentation ready:
With Teva's generic LAR now available, explicitly prescribing generic Octreotide LAR (rather than brand Sandostatin LAR) can save patients thousands per month. Make sure your prescription allows generic substitution unless there's a clinical reason to require brand.
Consider creating a handout or resource sheet for your Octreotide patients that includes:
Having this ready to hand patients at the point of prescribing eliminates the most common barrier: patients not knowing where to look for help.
When Octreotide formulations go on shortage, some patients may be pushed to more expensive alternatives or out-of-network pharmacies. Stay aware of current availability through the FDA Drug Shortage Database and Medfinder's provider tools.
Octreotide is a clinically essential medication for your patients with acromegaly, carcinoid syndrome, and neuroendocrine tumors. But at $3,000 to $10,000 per month, the financial burden is real — and it directly impacts adherence and outcomes.
The tools exist to make Octreotide more affordable: manufacturer programs, generic alternatives, foundation copay assistance, and proactive prescribing strategies. The key is building cost awareness into your clinical workflow so that savings conversations happen before patients face a crisis at the pharmacy counter.
For real-time pharmacy availability and stock checking, Medfinder for Providers can help you and your patients locate Octreotide quickly when it matters most.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
